Wells Fargo & Co upgraded shares of Illumina (NASDAQ:ILMN) from a market perform rating to an outperform rating in a research note released on Tuesday, January 2nd, MarketBeat reports. The firm currently has $205.00 price objective on the life sciences company’s stock.
Other equities analysts have also issued research reports about the stock. Deutsche Bank upgraded shares of Illumina from a hold rating to a buy rating and decreased their price target for the company from $195.00 to $160.00 in a report on Monday, October 23rd. Canaccord Genuity reissued a buy rating and issued a $230.00 target price (up previously from $215.00) on shares of Illumina in a research note on Thursday, October 12th. Vetr raised shares of Illumina from a hold rating to a buy rating and set a $217.50 target price on the stock in a research note on Tuesday, September 19th. Argus raised their target price on shares of Illumina from $205.00 to $235.00 and gave the company a buy rating in a research note on Wednesday, September 13th. Finally, Bank of America lifted their price target on shares of Illumina from $215.00 to $240.00 and gave the stock a buy rating in a research note on Wednesday, October 25th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average target price of $214.38.
Illumina (NASDAQ ILMN) traded down $0.21 during mid-day trading on Tuesday, hitting $242.59. 982,600 shares of the stock traded hands, compared to its average volume of 1,249,214. Illumina has a twelve month low of $156.50 and a twelve month high of $245.74. The firm has a market capitalization of $35,020.00, a price-to-earnings ratio of 45.77, a PEG ratio of 3.13 and a beta of 0.79. The company has a quick ratio of 3.73, a current ratio of 4.22 and a debt-to-equity ratio of 0.41.
Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. The firm had revenue of $714.00 million for the quarter, compared to analyst estimates of $692.77 million. Illumina had a net margin of 30.34% and a return on equity of 19.42%. Illumina’s revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the business earned $0.97 earnings per share. sell-side analysts expect that Illumina will post 3.75 EPS for the current year.
In other news, Director Robert S. Epstein sold 1,250 shares of the business’s stock in a transaction that occurred on Saturday, December 29th. The shares were sold at an average price of $217.38, for a total transaction of $271,725.00. Following the sale, the director now owns 8,838 shares in the company, valued at $1,921,204.44. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Omead Ostadan sold 3,540 shares of the business’s stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $226.91, for a total transaction of $803,261.40. Following the sale, the executive vice president now owns 26,827 shares in the company, valued at approximately $6,087,314.57. The disclosure for this sale can be found here. Insiders have sold a total of 137,671 shares of company stock valued at $29,485,768 over the last three months. 0.89% of the stock is currently owned by company insiders.
Hedge funds have recently bought and sold shares of the business. Intellectus Partners LLC grew its position in Illumina by 6.6% in the second quarter. Intellectus Partners LLC now owns 10,783 shares of the life sciences company’s stock worth $1,871,000 after acquiring an additional 664 shares in the last quarter. Stephens Investment Management Group LLC raised its stake in shares of Illumina by 0.5% in the 2nd quarter. Stephens Investment Management Group LLC now owns 168,706 shares of the life sciences company’s stock valued at $29,274,000 after buying an additional 803 shares in the last quarter. Axiom International Investors LLC DE raised its stake in shares of Illumina by 60.9% in the 3rd quarter. Axiom International Investors LLC DE now owns 186,457 shares of the life sciences company’s stock valued at $37,142,000 after buying an additional 70,572 shares in the last quarter. Virtu Financial LLC acquired a new position in shares of Illumina in the 3rd quarter valued at $577,000. Finally, Andra AP fonden acquired a new position in shares of Illumina in the 2nd quarter valued at $1,128,000. 91.60% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Illumina (ILMN) Raised to “Outperform” at Wells Fargo & Co” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/wells-fargo-co-upgrades-illumina-ilmn-to-outperform.html.
Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.